Contraindications: Pharma Group Deca-Duraboline is contraindicated in individuals with prostate or breast carcinoma, severe hepatic impairment, nephrotic syndrome, hypercalcaemia, or known hypersensitivity to nandrolone or any excipient. Pregnancy and breastfeeding are absolute contraindications. Paediatric use is contraindicated due to premature epiphyseal closure risk.
Side_Effects: Nandrolone Decanoate, as a 19-nor compound, elevates serum prolactin in a dose-correlated pattern; gynecomastia of the prolactin-mediated type may emerge in susceptible individuals during extended bulking cycles. Androgenic effects — acne, accelerated androgenic alopecia in genetically predisposed users, and virilisation in female users — occur at supraphysiological doses. Haematocrit elevation and HDL suppression are cardiovascular-relevant haematological changes that require monitoring throughout a long bulk. Injection-site reactions including localised pain, induration, or transient warmth may occur; rotation of sites mitigates this.
Monitoring: Obtain baseline bloodwork including testosterone, LH, FSH, haematocrit, lipid panel, hepatic enzymes, prolactin, and PSA (men over 40) before cycle commencement. Repeat at cycle midpoint (week eight in a sixteen-week bulk) and at cycle conclusion. Cabergoline at 0.25mg twice weekly may be indicated prophylactically when prolactin trends above the upper reference range at mid-cycle assessment.
PCT: Because Nandrolone Decanoate suppresses the hypothalamic-pituitary-gonadal axis throughout the bulking cycle, a structured PCT using Clomiphene Citrate and/or Tamoxifen is mandatory after cycle conclusion. Allow sufficient clearance time — approximately three to four weeks post-final injection — before commencing PCT to avoid blunting SERM efficacy with residual plasma nandrolone.